Published by Coherent Market Insights
Posted on October 6, 2021
The Ioversol Market report presents the industry sales and revenue by companies, regions, type and application and forecast to 2028. This report also studies the market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porter’s Five Forces Analysis.
Click Here To Get Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/386
Ioversol, otherwise known as IOU peroxide, is used as a dialysis anticoagulant in hospitals for the treatment of dialysis patients and is used commercially for the treatment of toothache. It is an oxidizing agent for internal applications in the human body. The Ioversol chemical name is Isoflavones and contains seven carbon atoms with one hydrogen atom in common with many substances derived from plants (Isoflavones). Isoflavones are commonly found in fruits such as strawberry and lemon, and also in egg yolk and some vegetables, notably artichokes, parsley, beets, carrots, leek, and kidney beans. Ioversol (Iodine-Orient-containing Nutrient suspension) is generally used for the relief of inflammation and to treat infections, to prevent or reduce bleeding, as dialysis therapy and to increase blood flow and oxygenate blood
The growing prevalence of bone-related disorders is a prime factor driving the growth of the ioversol market. Increasing geriatric population around the globe which is increasing the prevalence of the various chronic disease. This has raised the demand for a various diagnostic tool such as X-ray which is another key factor fueling the growth of the market. According to the United Nation, by 2050, one in six people in the world will be over age 65 (16%), up from one in 11 in 2019 (9%). By 2050, one in four persons living in Europe and Northern America could be aged 65 or over. The rise in spending on the healthcare sector by government for improving the patient care is further anticipated to propel the growth of the ioversol market.
North America is projected to gain significant growth over the forecast period and this is attributed to the high prevalence of the bone-related disorder in the region which. In 2017, the number of Canadians affected by osteoporosis had increased to 2 million. By the year 2030, the number of hip fractures is expected to quadruple. Moreover, In Canadians of 40 years or older, 1.5 million (10%) reported having been diagnosed with osteoporosis. Thus the high prevalence of bone a related disorder is projected to foster the growth of the ioversol market.
Key Developments:
In December 2020, Guerbet (GBT), a global provider of medical imaging, announced that it received US Food and Drug Administration approval for the commercial sale of the Optiray® Imaging Bulk Package (IBP) (Ioversol Injection) in the United States.
Top Key Players Include In Ioversol Market: Liebel-Flarsheim Company LLC, Guerbet, Jiangsu Hengrui Medicine Co., Mallinckrodt Pharmaceuticals, Ultraject, China Resources Pharmaceutical Co., HB Ocean, Changzhou Highassay Chemical Co., Ltd., and various others.
Get This premium report with Instant US$ 2000 discount @ https://www.coherentmarketinsights.com/promo/buynow/386
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com
The post New Comprehensive Report on Ioversol Market with Complete Analysis of Leading Players Liebel-Flarsheim Company LLC, Guerbet, Jiangsu Hengrui Medicine Co., Mallinckrodt Pharmaceuticals appeared first on Gatorledger.
The Ioversol Market report presents the industry sales and revenue by companies, regions, type and application and forecast to 2028. This report also studies the market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porter’s Five Forces Analysis.
Click Here To Get Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/386
Ioversol, otherwise known as IOU peroxide, is used as a dialysis anticoagulant in hospitals for the treatment of dialysis patients and is used commercially for the treatment of toothache. It is an oxidizing agent for internal applications in the human body. The Ioversol chemical name is Isoflavones and contains seven carbon atoms with one hydrogen atom in common with many substances derived from plants (Isoflavones). Isoflavones are commonly found in fruits such as strawberry and lemon, and also in egg yolk and some vegetables, notably artichokes, parsley, beets, carrots, leek, and kidney beans. Ioversol (Iodine-Orient-containing Nutrient suspension) is generally used for the relief of inflammation and to treat infections, to prevent or reduce bleeding, as dialysis therapy and to increase blood flow and oxygenate blood
The growing prevalence of bone-related disorders is a prime factor driving the growth of the ioversol market. Increasing geriatric population around the globe which is increasing the prevalence of the various chronic disease. This has raised the demand for a various diagnostic tool such as X-ray which is another key factor fueling the growth of the market. According to the United Nation, by 2050, one in six people in the world will be over age 65 (16%), up from one in 11 in 2019 (9%). By 2050, one in four persons living in Europe and Northern America could be aged 65 or over. The rise in spending on the healthcare sector by government for improving the patient care is further anticipated to propel the growth of the ioversol market.
North America is projected to gain significant growth over the forecast period and this is attributed to the high prevalence of the bone-related disorder in the region which. In 2017, the number of Canadians affected by osteoporosis had increased to 2 million. By the year 2030, the number of hip fractures is expected to quadruple. Moreover, In Canadians of 40 years or older, 1.5 million (10%) reported having been diagnosed with osteoporosis. Thus the high prevalence of bone a related disorder is projected to foster the growth of the ioversol market.
Key Developments:
In December 2020, Guerbet (GBT), a global provider of medical imaging, announced that it received US Food and Drug Administration approval for the commercial sale of the Optiray® Imaging Bulk Package (IBP) (Ioversol Injection) in the United States.
Top Key Players Include In Ioversol Market: Liebel-Flarsheim Company LLC, Guerbet, Jiangsu Hengrui Medicine Co., Mallinckrodt Pharmaceuticals, Ultraject, China Resources Pharmaceutical Co., HB Ocean, Changzhou Highassay Chemical Co., Ltd., and various others.
Get This premium report with Instant US$ 2000 discount @ https://www.coherentmarketinsights.com/promo/buynow/386
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com
The post New Comprehensive Report on Ioversol Market with Complete Analysis of Leading Players Liebel-Flarsheim Company LLC, Guerbet, Jiangsu Hengrui Medicine Co., Mallinckrodt Pharmaceuticals appeared first on Gatorledger.
Explore more articles in the Research Reports category
